Active Clinical Research for Solid Tumors

Comprehensive Cancer Centers is currently running the following Phase II and Phase III clinical research studies for solid tumors:

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements **Baskets open : NTRK 1/2/3 – All baskets will remain open, NSCLC (Evaluable and Non-Evaluable Basket), MCRC (Evaluable and Non-Evaluable Basket), All other small solid tumors (Evaluable and Non-Evaluable Basket), ROS1, MCRC (Evaluable from Primary Endpoint Only – Meets all Inc/Exc and has measurable disease), All other small solid tumors (Evaluable from Primary Endpoint Only – Meets all Inc/Exc and has measurable disease)**
Study#: i2281 Phase III
Contact Us: For information about this clinical study, Email Us, or use our form field.

A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001) **COHORTS 1 CLOSED TO NSCLC, COHORT 3 IS CLOSED TO ENROLLMENT, AND COHORT 5 REQUIRES SLOT RESERVATIONS**
Study#: i2647 Phase I/II
Contact Us: For information about this clinical study, Email Us, or use our form field.

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) **Cohort A: FGFR1-3 in-frame fusions or FGFR2 intron 17 rearrangements, Cohort B: Known/predicted activating point mutations in FGFR1-3 (excluding kinase domain, Cohort C: Any FGFR1-3 point mutations in the kinase domain or FGFR1/FGFR3 rearrangements with unknown partners and variants of unknown significance**
Study#: i2689 Phase II
Contact Us: For information about this clinical study, Email Us, or use our form field.

A Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors **ONLY NSCLC OPEN TO ENROLLMENT**
Study#: i2691 Phase II
Contact Us: For information about this clinical study, Email Us, or use our form field.

A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial
Study#: i2716 Phase III
Contact Us: For information about this clinical study, Email Us, or use our form field.

“An Open-label, Multicenter, Multi-cohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects with Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) **ENROLLMENT ON HOLD**”
Study#: i2743 Phase II
Contact Us: For information about this clinical study, Email Us, or use our form field.

“A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors”
Study#: i2737 Phase I
Contact Us: For information about this clinical study, Email Us, or use our form field.

Phase 1/2a, Open-Label, Multicenter Study To Assess The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of PEN-866 In Patients With Advanced Solid Malignancies
Study#: 12752 Phase II
Contact Us: For information about this clinical study, Email Us, or use our form field.

A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)
Study#: 19092 Phase II
Contact Us: For information about this clinical study, Email Us, or use our form field.

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Study#: 19151 Phase II
Contact Us: For information about this clinical study, Email Us, or use our form field.